{
    "Trade/Device Name(s)": [
        "ONLINE TDM Carbamazepine Gen. 4"
    ],
    "Submitter Information": "Roche Diagnostics Operations (RDO)",
    "510(k) Number": "K151578",
    "Predicate Device Reference 510(k) Number(s)": [
        "K031902"
    ],
    "Regulatory Class": "II",
    "Product Code(s)": [
        "KLT"
    ],
    "Summary Letter Date": "September 21, 2015",
    "Summary Letter Received Date": "September 22, 2015",
    "Submission Date": "October 22, 2015",
    "Regulation Number(s)": [
        "21 CFR 862.3645"
    ],
    "Regulation Name(s)": [
        "Neuroleptic drugs radioreceptor assay test system"
    ],
    "Analyte Class(es)": [
        "tdm",
        "chemistry",
        "toxicology"
    ],
    "Analyte(s)": [
        "Carbamazepine"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Standard sampling tube",
        "Gel separation tube",
        "K2-EDTA tube",
        "K3-EDTA tube",
        "Sodium heparin tube",
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Roche/Hitachi cobas c systems",
        "Automated clinical chemistry analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous microparticle agglutination immunoassay",
        "Kinetic interaction of microparticles in solution (KIMS)"
    ],
    "Methodologies": [
        "Immunoassay",
        "Microparticle agglutination",
        "Competitive binding assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Roche ONLINE TDM Carbamazepine Gen. 4 immunoassay for quantification of carbamazepine in serum and plasma",
    "Indications for Use Summary": "In vitro quantitative determination of carbamazepine in serum and plasma on Roche/Hitachi cobas c systems to monitor carbamazepine therapy levels",
    "fda_folder": "Toxicology"
}